Evening With the Experts: Next Generation Predictive Biomarkers and Targeted Therapies in GI Cancers

Join us for this case-based, interactive, CME-certified symposium held in conjunction with the 2023 Gastrointestinal Cancers Symposium featuring expert perspectives on molecular testing, predictive biomarkers, and targeted therapy for patients with GI malignancies. Bring your questions for the live Q&A session with the expert panel at the end of the session.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Clinical Care Options, LLC is committed to providing a safe and healthy environment for all our learners. Our decisions and preventive measures are guided by the requirements and recommendations of the CDC alongside federal, state, and local health authorities. We work with each program venue to implement preventive measures to reduce the potential spread of COVID-19. In addition, ASCO will refer to the CDC COVID-19 Community Levels (Low, Medium, High) and associated Prevention Actions to guide health precautions for in-person meetings.

For more information on ASCO’s vaccination and mask requirements, please visit: ASCO’s website

Not an official event of the 2023 ASCO Gastrointestinal Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation.

Agenda

  • Welcome and Overview
  • Barriers to Precision Medicine for GI Cancers
  • Case Discussions: Updates in Biomarker Testing and Targeted Therapy Across GI Cancers
    • Actionable biomarkers: who to test and what to test for
    • Expert targeted treatment recommendations
  • Live Audience Question and Answer Session

Events

Date / Time
Event Details

Faculty

Program Director
John L. Marshall, MD

Chief, Division of Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

Faculty
Christopher H. Lieu, MD

Associate Professor
Associate Director for Clinical Research

Division of Medical Oncology
University of Colorado Cancer Center
Co-Director
Division of Medical Oncology
University of Colorado Hospital
Aurora, Colorado

Faculty
Manish A. Shah, MD

Bartlett Family Professor of Gastrointestinal Oncology
Chief, 
Solid Tumor Services
Director, Gastrointestinal Oncology Program
Weill Cornell Medical College
New York, New York

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in the assessment of predictive biomarkers to guide the individualized treatment of patients with gastrointestinal malignancies.

Target Audience
This educational program is intended for medical oncologists and other healthcare professionals who treat patients with gastrointestinal cancers.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Implement evidence-based molecular testing in GI cancers, including BRAF V600E, HER2/HER3, BRCA1/2, FGFR2, IDH1, and histology-agnostic markers
  • Plan targeted therapeutic strategies for patients with GI malignancies based on predictive biomarker assessment, available data, and expert recommendations
  • Counsel patients about their tumor molecular profile and how this information will guide therapy decisions
  • Identify patients with GI malignancies eligible for enrollment in ongoing clinical trials of novel biomarker-driven treatment strategies

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.